Abstract
The activity of cefotaxime, either alone or combined with an aminoglycoside, was determined against 50 isolates of Pseudomonas aeruginosa, of which 50, 33, and 10 were resistant to gentamicin, tobramycin, and amikacin, respectively. Cefotaxime inhibited 34 isolates at a concentration of 16 microgram/ml and all isolates at 128 microgram/ml. The combinations of cefotaxime with gentamicin, tobramycin, and amikacin were synergistic against 30, 17, and 9 isolates, respectively, and no antagonism was observed with any combination. Synergism was obtained at clinically significant antibiotic concentrations for nine isolates with cefotaxime-gentamicin, five isolates with cefotaxime-tobramycin, and nine isolates with cefotaxime-amikacin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chanbusarakum P., Murray P. R. Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics. Antimicrob Agents Chemother. 1978 Sep;14(3):505–506. doi: 10.1128/aac.14.3.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Drasar F. A., Farrell W., Howard A. J., Hince C., Leung T., Williams J. D. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods. J Antimicrob Chemother. 1978 Sep;4(5):445–450. doi: 10.1093/jac/4.5.445. [DOI] [PubMed] [Google Scholar]
- Hamilton-Miller J. M., Brumfitt W., Reynolds A. V. Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro. J Antimicrob Chemother. 1978 Sep;4(5):437–444. doi: 10.1093/jac/4.5.437. [DOI] [PubMed] [Google Scholar]
- Klastersky J., Hensgens C., Debusscher L. Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother. 1975 May;7(5):640–645. doi: 10.1128/aac.7.5.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Murray P. R., Christman J. L., Medoff G. In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1979 Mar;15(3):452–454. doi: 10.1128/aac.15.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Aswapokee N., Aswapokee P., Fu K. P. HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1979 Feb;15(2):273–281. doi: 10.1128/aac.15.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shah P. M., Troche G., Stille W. In vitro activity of HR 756, a new cephalosporin compound. J Antibiot (Tokyo) 1978 Nov;31(11):1170–1174. doi: 10.7164/antibiotics.31.1170. [DOI] [PubMed] [Google Scholar]
- Sosna J. P., Murray P. R., Medoff G. Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole. Antimicrob Agents Chemother. 1978 Dec;14(6):876–879. doi: 10.1128/aac.14.6.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wade J. C., Smith C. R., Petty B. G., Lipsky J. J., Conrad G., Ellner J., Lietman P. S. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet. 1978 Sep 16;2(8090):604–606. doi: 10.1016/s0140-6736(78)92825-8. [DOI] [PubMed] [Google Scholar]